Amalgamated Bank’s Meridian Bioscience Inc VIVO Stock Holding History

Amalgamated Bank’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-21,084	Closed	-$700K	–	2973
2022 Q4	$700K	Hold	21,084	–	–	0.01%	1302
2022 Q3	$665K	Buy	21,084 +247	+1%	+$8K	0.01%	1283
2022 Q2	$634K	Buy	20,837 +1,248	+6%	+$33.8K	0.01%	1353
2022 Q1	$509K	Sell	19,589 -1,005	-5%	-$23.9K	﹤0.01%	1539
2021 Q4	$420K	Sell	20,594 -555	-3%	-$10.6K	﹤0.01%	1659
2021 Q3	$407K	Sell	21,149 -328	-2%	-$6.54K	﹤0.01%	1693
2021 Q2	$476K	Buy	+21,477	New	+$456K	﹤0.01%	1673

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Amalgamated Bank's VIVO Position: Q1 2023 in Review

Amalgamated Bank sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 21,084 shares — an estimated $700K sold.

Amalgamated Bank first reported a position in VIVO in Q2 2021 and held it in 7 quarters. The position peaked at $700K in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Amalgamated Bank reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Amalgamated Bank sold 21,084 Meridian Bioscience Inc shares in Q1 2023, an estimated $700K.
Amalgamated Bank first reported a position in Meridian Bioscience Inc in Q2 2021 and held it in 7 quarters.
Amalgamated Bank's Meridian Bioscience Inc position peaked at $700K in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Amalgamated Bank's 13F filing for Q1 2023, filed 2 May 2023.